ArticleNature2021
High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape.
Open access · bronzeAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 148 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
148citing papers in PubMed, 1 pooled it
13.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
148 citing papers in PubMed, 1 synthesis or guideline pooled it, 238 citations in OpenAlex.
- Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources.Nature communications · 2022Pooled it
- SARS-CoV-2 variants with reduced infectivity and varied sensitivity to the BNT162b2 vaccine are developed during the course of infection.PLoS pathogens · 2022Trial
- A designed overlapping variant immunogen pool elicits broad sarbecovirus neutralization.bioRxiv : the preprint server for biology · 2026Article
- Impaired neutralizing antibody responses against the BA1.1, BA.2, and BA.5 Omicron SARS-CoV-2 subvariants in hospitalized adults infected with pre-Omicron variants in Argentina.Microbiology spectrum · 2026Article
- Memory B cell development in response to mRNA SARS-CoV-2 and nanoparticle immunization in mice.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- COVID-19 convalescent plasma safety and efficacy analysis for biologics license application approval.Expert review of anti-infective therapy · 2026Review
- Spike conformational and glycan heterogeneity associated with furin cleavage causes incomplete neutralization of SARS-CoV-2.Nature communications · 2025Article
- Viral evolution prediction identifies broadly neutralizing antibodies to existing and prospective SARS-CoV-2 variants.Nature microbiology · 2025Article
- A replicating recombinant vesicular stomatitis virus model for dairy cattle H5N1 influenza virus glycoprotein evolution.Journal of virology · 2025Article
- Article
- Estimating cumulative infection rate of COVID-19 after adjusting the dynamic zero-COVID policy in China.Infectious Disease Modelling · 2025Article
- In depth sequencing of a serially sampled household cohort reveals the within-host dynamics of Omicron SARS-CoV-2 and rare selection of novel spike variants.PLoS pathogens · 2025Article
- Effect of mild-to-moderate COVID‑19 on the incidence and risk factors for deep vein thrombosis in patients with hip fracture: a retrospective study.BMC surgery · 2025Article
- A replicating recombinant vesicular stomatitis virus model for dairy cattle H5N1 influenza virus glycoprotein evolution.bioRxiv : the preprint server for biology · 2025Article
- COVID-19 convalescent plasma for B-cell depleted patients: a systematic review and individual patient data meta-analysis.Frontiers in medicine · 2025Article
- Antibodies to the RBD of SARS-CoV-2 spike mediate productive infection of primary human macrophages.Nature communications · 2024Article
- Symptomatology and IgG Levels before and after SARS-CoV-2 Omicron Breakthrough Infections in Vaccinated Individuals.Vaccines · 2024Article
- A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system.PLoS pathogens · 2024Article
- Article
- A VHH single-domain platform enabling discovery and development of monospecific antibodies and modular neutralizing bispecifics against SARS-CoV-2 variants.Antibody therapeutics · 2024Article
88 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors at 2 institutions in 1 country.
Fabian Schmidt *Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Yiska Weisblum *Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Magdalena RutkowskaHoward Hughes Medical Institute, The Rockefeller University, New York, NY, USA.
Daniel PostonLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0001-9900-6717
Justin DaSilvaLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0001-6393-0000
Fengwen ZhangLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Eva BednarskiLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Alice ChoLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Dennis J Schaefer-BabajewLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0002-5380-2950
Christian GaeblerLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0001-7295-8128
Marina CaskeyLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0003-1727-8693
Michel C NussenzweigHoward Hughes Medical Institute, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0003-0592-8564
Theodora HatziioannouLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA. thatziio@rockefeller.edu.ORCID http://orcid.org/0000-0002-7889-0766
Paul D BieniaszLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA. pbieniasz@rockefeller.edu.ORCID http://orcid.org/0000-0002-2368-3719
Rockefeller University · USHoward Hughes Medical Institute · US
Funding
Weill Cornell/Rockefeller/Sloan-Kettering MST ProgramT32GM007739 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI HSU, KATHARINE C · 1985 to 2023
$51.1MDeveloping, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6MUnderstanding B cell memory in response to diverse virus infectionsU19AI111825 · NIAID · ROCKEFELLER UNIVERSITY · PI BOURNAZOS, STYLIANOS · 2014 to 2023
$26.0MOvercoming Host Restriction Factors to Develop Better Animal Models for HIV/AIDS.R01AI078788 · NIAID · ROCKEFELLER UNIVERSITY · PI HATZIIOANNOU, THEODORA · 2008 to 2021
$9.3MRNA Protein interactions in HIV-1 replicationR01AI050111 · NIAID · ROCKEFELLER UNIVERSITY · PI BIENIASZ, PAUL D. · 2001 to 2021
$7.9MDiscovery and Mechanism of Antiretroviral FactorsR37AI064003 · NIAID · ROCKEFELLER UNIVERSITY · PI BIENIASZ, PAUL D. · 2011 to 2020
$4.9MElucidating antiviral defenses against diverse immunodeficiency viruses using a novel, high-throughput CRISPR/Cas9 screening method.F30AI157898 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI POSTON, DANIEL · 2021 to 2024
$191kHoward Hughes Medical InstituteNCATS NIH HHS UL1 TR001866NIAID NIH HHS F30 AI157898NIAID NIH HHS R01 AI050111NIAID NIH HHS R01 AI078788NIAID NIH HHS R37 AI064003NIAID NIH HHS U19 AI111825NIGMS NIH HHS T32 GM007739NIH HHS 2U19 AI111825
Abstract
The number and variability of the neutralizing epitopes targeted by polyclonal antibodies in individuals who are SARS-CoV-2 convalescent and vaccinated are key determinants of neutralization breadth and the genetic barrier to viral escape
Indexed as
Immune EvasionMutationAntibodies, NeutralizingAntibodies, ViralConvalescenceCOVID-19Cross ReactionsHumansImmune SeraNeutralization TestsSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralImmune SeraSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.